This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Beta Bionics, Inc. (BBNX) and Twist Bioscience (TWST)

Tipranks - Tipranks - Sat May 23, 7:08AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV), Beta Bionics, Inc. (BBNX) and Twist Bioscience (TWST) with bullish sentiments.

Meet Samuel – Your Personal Investing Prophet

IQVIA Holdings (IQV)

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings. The company’s shares closed last Thursday at $168.02.

According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of -12.6% and a 35.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $215.90 average price target, representing a 26.6% upside. In a report issued on May 8, TipRanks – Google also upgraded the stock to Buy with a $197.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Beta Bionics, Inc. (BBNX)

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Beta Bionics, Inc.. The company’s shares closed last Thursday at $10.61.

According to TipRanks.com, Newitter is a 4-star analyst with an average return of 7.0% and a 47.3% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Beta Bionics, Inc. is a Moderate Buy with an average price target of $18.17, which is an 82.6% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.

Twist Bioscience (TWST)

TD Cowen analyst Brendan Smith reiterated a Buy rating on Twist Bioscience today and set a price target of $68.00. The company’s shares closed last Thursday at $58.84, close to its 52-week high of $60.90.

According to TipRanks.com, Smith is a 4-star analyst with an average return of 6.4% and a 45.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Recursion Pharmaceuticals, and Ginkgo Bioworks Holdings. ;'>

Twist Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $63.43.

Read More on IQV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).